Condition
Advanced Solid Tumor, Adult
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07361562Phase 1RecruitingPrimary
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT04972110Phase 1TerminatedPrimary
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
NCT03729596Phase 1Terminated
MGC018 With or Without MGA012 in Advanced Solid Tumors
Showing all 3 trials